Fiche société
Momenta Pharmaceuticals, Inc.
Traitements, essais et publications liés.
Traitements2programmes
Essais1liés
Publications0liées
SourceDBlocale
Traitements
2| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| M281The purpose of this study is to evaluate the long-term safety and tolerability of M281 in participants with generalized myasthenia gravis (gMG) | Myasthénie | Phase 2 | À vérifier | United States, Belgium, Canada, Germany, Italy, Poland, Spain, United Kingdom | À vérifier |
| M281The purpose of this study is to evaluate the long-term safety and tolerability of M281 in participants with generalized myasthenia gravis (gMG) | Myasthénie | Phase 2 | À vérifier | United States, Belgium, Canada, Germany, Italy, Poland, Spain, United Kingdom | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| M281 | Myasthénie | Phase 2 | NCT03896295 | An Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia Gravis | TERMINATED |
Publications
0| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Aucune publication. | ||||